

Scheme 1. Solid-phase synthesis of **1a–b**.

support. Treatment with concentrated TFA permitted the concomitant deprotection of the side chains and of the isopropylidene tartrate moiety, thus unmasking the vicinal diol of the linker. The final periodic oxidation required the presence of a lipophilic co-solvent to allow the swelling of the beads, whose interior was highly hydrophobic due to the presence of the palmitoyl groups. The best results were obtained using an acetic acid/water/methyl-2-propanol-2 1/2/3 (by vol.) mixture. Both compounds **1a** and **1b** were found to be insoluble in this solvent mixture, so that precipitation of the product occurred inside the beads, which were washed with water to remove the salts and ethanolamine used to quench the excess of periodate. The products were then extracted from the beads using methyl-2-propanol-2/MeOH and MeOH/CH₂Cl₂ at 50°C. Using this procedure, **1a** and **1b** were isolated in high purity and with 20 and 40% yield, respectively.¹¹

The spacer of **1a** was designed to incorporate a UV chromophore and a positively charged group for RP-HPLC and mass spectrometry characterizations, respectively. Compound **1a** was found to be scarcely soluble in organic solvents usually employed for liposome preparation, but dissolved in the presence of DMPC, DMPG and cholesterol.¹² Hydrazone ligation with liposomes incorporating **1a** was studied using model α -hydrazino acetyl peptide H₂N-GRYL-NH₂ **5**.¹³ Control experiments were performed with Ac-RYL-NH₂ **6** (**1a/5** or **1a/6**: 1 equiv./1 equiv.). Quantification of the amount of peptide associated with liposomes or remaining in solution was performed by amino acid analysis following total acid hydrolysis. 50% of peptide **5** was found to be associated with liposomes (20% for **6** probably due to ionic and/or hydrophobic interactions). The remaining of the peptide was found in solution, showing that the presence of phospholipids did not alter the amino acid analysis. The better association of peptide **5** with functional liposomes could be

attributed to the formation of covalent hydrazone linkages. If one assumes a statistical distribution of **1a** into the liposome bilayer and that the membrane is not permeable to peptides **5** or **6**, the maximum yield for hydrazone ligation should be 50%, i.e. what was effectively obtained experimentally.

To solve the solubility problems associated with **1a**, a second spacer was designed based on the assembly of hydrophilic building blocks. Compound **1b** was effectively found to be more soluble in organic or partially organic solvents. Interestingly, **1b** unlike its parent **1a**, could be successfully engaged in hydrazone ligation in solution. Indeed, reaction of **1b** with α -hydrazino acetyl peptide **7** led to the formation of compound **8** with 41% yield following RP-HPLC purification (Fig. 2). Fig. 2 highlights the efficacy of the process, since the conversion was found to be as high as 60% after few seconds of reaction at 37°C. The same ligation proceeded successfully (60% yield) when **1b** was incorporated into liposomes which behaved as very efficient tools for the specific picking of proteins in a complex cytosolic medium.

In conclusion, a novel evolutionary family of amphiphilic α -oxo aldehydes for membrane immobilization through hydrazone ligation has been described. Studies devoted to the biological evaluation of the liposomes will be reported in due course.

Acknowledgements

We thank Pascale Chenevier (UPR 8641 CNRS, Centre de Recherche Paul Pascal, Pessac) and Dr. Eve-Isabelle Pécheur-Huet (FRE 2377 CNRS, Institut de Biologie de Lille) for scientific discussions, Hervé Drobecq and Vianney Souplet for technical assistance. We gratefully




Figure 2. Ligation in solution of **1b** with peptide **7**. RP-HPLC monitoring of hydrazone ligation.

acknowledge financial support from Institut Pasteur de Lille, Université de Lille 2, Agence Nationale de Recherche sur le SIDA (ANRS) and Centre National de la Recherche Scientifique (CNRS).

References

- Hojo, H.; Kojima, T.; Yamauchi, K.; Kinoshita, M. *Tetrahedron Lett.* **1996**, *37*, 7391–7394.
- (a) Sugimoto, M.; Ohishi, K.; Fukasawa, M.; Shikata, K.; Kawai, H.; Itakura, H.; Hatanaka, M.; Sakakibara, R.; Ishiguro, M.; Nakata, M.; Mizuochi, T. *FEBS Lett.* **1995**, *363*, 53–56; (b) Fukasawa, M.; Shimizu, Y.; Shikata, K.; Nakata, M.; Sakakibara, R.; Yamamoto, N.; Hatanaka, M.; Mizuochi, T. *FEBS Lett.* **1998**, *441*, 353–356.
- Epand, R. M. *Biopolymers* **1997**, *43*, 15–24.
- Kung, V. T.; Redeman, C. T. *Biochim. Biophys. Acta* **1986**, *862*, 435–439.
- (a) Boeckler, C.; Frisch, B.; Schuber, F. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2055–2058; (b) Schelré, P.; Boeckler, C.; Frisch, B.; Schuber, F. *Bioconj. Chem.* **2000**, *11*, 118–123; (c) Martin, F. J.; Papahadjopoulos, D. *J. Biol. Chem.* **1982**, *257*, 286–288; (d) Heeremans, J.; Kraaijenga, J.; Los, P.; Kluft, C.; Crommelin, D. *Biochim. Biophys. Acta* **1992**, *1117*, 258–264; (e) Kamps, J.; Swart, P.; Morselt, H.; Pauwels, R.; De Béthune, M.-P.; De Clerck, E.; Meijer, D.; Scherphof, G. *Biochim. Biophys. Acta* **1996**, *1278*, 183–190.
- Barbet, J.; Machy, P.; Leserman, L. *J. Supramol. Chem. Cell. Biochem.* **1981**, *16*, 243–258.
- (a) Melnyk, O.; Fehrentz, J.-A.; Martinez, J.; Gras-Masse, H. *Biopolymers (Peptide Sci.)* **2000**, *55*, 165–186; (b) An α -oxo hydrazone ligation was successfully applied to the synthesis of lipo-peptides modified by a single lipidic tail, see: Bonnet, D.; Bourel, L.; Gras-Masse, H.; Melnyk, O. *Tetrahedron Lett.* **2000**, *41*, 10003–10007.
- (a) Fruchart, J.-S.; Gras-Masse, H.; Melnyk, O. *Tetrahedron Lett.* **1999**, *40*, 6225–6228; (b) Melnyk, O.; Fruchart, J.-S.; Grandjean, C.; Gras-Masse, H. *J. Org. Chem.* **2001**, *66*, 4153–4160; (c) Melnyk, O.; Fruchart, J.-S.; Bourel, L.; Gras-Masse, H. Patent application FR 99-05024 and PCT/FR00/01035.
- Chan, W.; White, P. In *Fmoc Solid Phase Peptide Synthesis, A Practical Approach*; Chan, W.; White, P., Eds.; Oxford University Press: Oxford, 2000; pp. 41–76.
- Olah, G.; Nojima, M.; Kereles, I. *Synthesis* **1973**, 487.
- 1a**: MALDI-TOF $[M+Na]^+$ calcd: 1048, found 1048. **1b**: MALDI-TOF $[M+Na]^+$ calcd: 1295.7, 1295.0, NMR ($CDCl_3/CD_3OD$ 1/1 by vol., 300 MHz) 1H δ ppm 0.80 (t, $J=6.7$ Hz, 6H), 1.15 (m, 50H), 1.35 (m, 2H), 1.50 (m, 5H), 1.66 (m, 7H), 1.80 (m, 2H), 2.15 (m, 4H), 2.85 (m, 2H), 3.10 (m, 4H), 3.20–3.50 (m, 16H), 3.50 (m, 16H), 3.80 (s, 2H), 4.00 (s, 2H), 4.05 (s, 2H), 4.15 (t, $J=5.6$ Hz, 1H), 4.35 (m, 1H), 6.65 (d, $J=8.3$ Hz, 2H), 6.90 (d, $J=8.3$ Hz, 2H). ^{13}C δ ppm 13, 28, 36, 42, 48, 53, 60, 69, 95.
- Large unilamellar vesicles: dimyristoyl phosphatidyl choline/dimyristoyl phosphatidyl glycerol/cholesterol/**1a** (54/42/6/10 by mol). Rehydration by a citrate/phosphate buffer 50 mM, pH 6.
- Bonnet, D.; Ollivier, N.; Gras-Masse, H.; Melnyk, O. *J. Org. Chem.* **2001**, *66*, 443–449.